New Four-Pronged attack on advanced liver cancer enters testing
NCT ID NCT07422753
Summary
This study is testing a combination of four treatments for advanced liver cancer that cannot be removed by surgery. It aims to see if adding a new drug (ipilimumab N01) to a standard three-part regimen is safe and more effective. Researchers will enroll 36 adults and compare three different treatment schedules to find the best approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.